Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Glesatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AMETHYST
- Sponsors Mirati Therapeutics
- 29 Nov 2017 This trial has been suspended in Spain.
- 08 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 28 Jun 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.